Why Prolia May be the Better Drug for Reducing Bone Breaks and Recurrence After Breast Cancer

Forbes—December 11, 2015

Forbes contributor Elaine Schattner reports on a major drug trial aimed to reduce fractures and bone breaks in those with cancer diagnoses. There is a huge population of breast cancer survivors who are menopausal and at high risk for fractures.

According to Linda A. Russell, MD, a rheumatologist at Hospital for Special Surgery, patients tolerate Prolia [the drug] well.

"With oral bisphosphonates, some people do have symptoms like heartburn," Dr. Russell said. "With infusions of bisphosphonates, patients sometimes get flu-like symptoms. You really don't see that with Prolia."

To read the full article, please visit Forbes.com.